Bruker Corporation (BRKR) is Reiterated by Barclays to Overweight, Raises Price Target to $ 32

Bruker Corporation (BRKR) was Reiterated by Barclays to “Overweight” according to the research note released today. The brokerage firm has raised the Price Target to $ 32 from a previous price target of $30 . Barclays advised their investors in a research report released on May 5, 2016.

Many Wall Street Analysts have commented on Bruker Corporation. Company shares were Reiterated by Mizuho on May 5, 2016 to “Neutral”, Firm has raised the Price Target to $ 28 from a previous price target of $22 .Bruker Corporation was Downgraded by Leerink Partners to ” Mkt Perform” on Apr 5, 2016. Bruker Corporation was Downgraded by BofA/Merrill to ” Underperform” on Apr 5, 2016.

On the company’s financial health, Bruker Corporation reported $0.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on May 4, 2016. Analyst had a consensus of $0.15. The company had revenue of $375.40 million for the quarter, compared to analysts expectations of $360.07 million. The company’s revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 EPS.

Bruker Corporation closed down -0.43 points or -1.53% at $27.65 with 10,46,335 shares getting traded on Wednesday. Post opening the session at $27.88, the shares hit an intraday low of $27.55 and an intraday high of $27.92 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Mar 14, 2016, Mark Munch (Exec VP&Pres Bruker Nano Inc.) sold 75,000 shares at $27.70 per share price. According to the SEC, on Jun 17, 2015, Frank H Laukien (CEO) purchased 1,000,000 shares at $19.50 per share price. On Jun 15, 2015, Stephen W. Fesik (director) sold 15,000 shares at $20.48 per share price, according to the Form-4 filing with the securities and exchange commission.

Bruker Corporation is a designer and manufacturer of life science and materials research systems and associated products that address the needs of a range of customers in life science research pharmaceuticals applied markets nanotechnology cell biology clinical research microbiology and in-vitro diagnostics. The Company operates through two segments: Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST). BSI is organized into three operating segments: the Bruker BioSpin Group the Bruker CALID Group and the Bruker Nano Group. BEST designs manufactures and distributes superconducting materials. The company maintains technical and manufacturing centers in Europe and North America and it has sales offices located throughout the world.

Bruker Corporation

Leave a Reply

Bruker Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bruker Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.